Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Appointment of New Director

On October 19, 2021, the Board of Directors (the "Board") of Dynavax Technologies Corporation (the "Company") appointed Scott Myers to serve as a Class I Director and Chairman of the Board, effective immediately, to serve until the 2022 Annual Meeting of Stockholders, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board does not currently intend to appoint Mr. Myers to any committees of the Board.

Pursuant to the Company's non-employee director compensation policy, as amended, (the "Policy"), a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K, on the date of his appointment Mr. Myers was granted a Nonstatutory Stock Option ("NSO") to purchase 45,000 shares of the Company's Common Stock with exercise price of $17.55 per share, which is equal to the closing price of the Company's Common Stock on October 19, 2021, as reported on the Nasdaq Capital Market, and 10,714 Restricted Stock Units ("RSU").The NSO and RSU were granted under the Company's 2018 Equity Incentive Plan and vest over three years in equal annual installments on the anniversary of the grant date, provided that Mr. Myers continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until Mr. Myers no longer provides services to the Company. Mr. Myers will also receive an annual cash retainer of $100,000 for service as Chairman of the Board.

There are no arrangements or understandings between Mr. Myers and any other person pursuant to which Mr. Myers was appointed as a director of the Company, and there are no family relationships between Mr. Myers and any of the Company's other directors or executive officers. Mr. Myers is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K.

The Company will enter into its standard form of indemnification agreement (the "Indemnity Agreements") with Mr. Myers. The Indemnity Agreement provides, among other things, that the Company will indemnify Mr. Myers, under the circumstances and to the extent provided therein, for certain expenses which he may be required to pay in connection with certain claims to which he may be made a party by reason of his service to the Company as a director, and otherwise to the fullest extent under applicable law. The foregoing is only a brief description of the terms of the indemnification arrangement with Mr. Myers, does not purport to be complete, and is qualified in its entirety by reference to the form of Indemnification Agreement, previously filed as Exhibit 10.19 to the Company's Annual Report on Form 10-K for the period ended December 31, 2020, as filed on February 25, 2021.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
Number       Exhibit Description

99.1           Dynavax Technologies Corporation Non-Employee Director Compensation
             Policy, effective October 2021.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses